Big pharma is grappling with new drug pricing deals and roughly $300 billion in potential lost revenue from patent ...

Investors expect a surge in deal activity in 2026 as drug makers look to replenish pipelines and capitalize on low interest ...

The global, double-blinded phase 3 study enrolled 165 patients aged between 12 and 75 years and measured the time to onset ...

Life sciences mergers and acquisitions surged back in force in 2025, as pharmaceutical and med-tech companies moved ...

The news comes on the heels of President Trump calling for Congress to enact his most recent attempt to lower healthcare costs in America, The Great Healthcare Plan. The proposal is a series of ...

Enter generative AI, which the pharma industry is adopting at a terrific rate. By ingesting and analysing vast biological ...

Danish dermatology specialist Leo Pharma and its CEO Christophe Bourdon came to San Francisco to attend the J.P. Morgan ...

From the corporate jets of Teterboro Airport to the crowded halls of the J.P. Morgan Healthcare Conference, it’s a good time ...

According to reporting from Bloomberg at the J.P. Morgan Healthcare Conference that ended today in San Francisco, ...

AbbVie struck a big deal to enter the hot PD-1xVEGF bispecific space. | In this week's Asia news recap, AbbVie struck a big ...

We expect increased deal activity to continue in 2026, driven by the looming patent cliff and reduced uncertainty for the ...

Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate R&D, betting on new modeling tools ...